Palvella Therapeutics, Inc Cash Flow Conversion Efficiency
Palvella Therapeutics, Inc cash flow conversion efficiency. Based on the latest financial reports, Palvella Therapeutics, Inc (PVLA) has a cash flow conversion efficiency ratio of -0.059x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.85 Million) by net assets ($216.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Palvella Therapeutics, Inc (2020–2025)
Cash flow conversion efficiency of Palvella Therapeutics, Inc from 2020 to 2025. This chart illustrates how Palvella Therapeutics, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Palvella Therapeutics, Inc for real-time trading data and today's change.
Palvella Therapeutics, Inc Cash Flow Conversion Ratio Explained
Palvella Therapeutics, Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Palvella Therapeutics, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Palvella Therapeutics, Inc ranked by their cash flow conversion efficiency. Also see how much is Palvella Therapeutics, Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sichuan Development Lomon Co Ltd
SHE:002312
|
0.017x |
|
Lily Group Co Ltd
SHG:603823
|
0.020x |
|
Chongqing Fuling Electric Power Industrial Co Ltd
SHG:600452
|
0.061x |
|
Garware Hi-Tech Films Limited
NSE:GRWRHITECH
|
0.061x |
|
Wuxi Rural Commercial Bank Co Ltd
SHG:600908
|
-0.061x |
|
Dicker Data Ltd
AU:DDR
|
0.120x |
|
Optowide Technologies Co. Ltd. A
SHG:688195
|
N/A |
|
GQG PARTNERS CDI/1/1
F:6P1
|
N/A |
Annual Cash Flow Conversion Efficiency for Palvella Therapeutics, Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of Palvella Therapeutics, Inc from 2020 to 2025. Review PVLA financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.98 Million | $-25.01 Million | -0.894x | -416.11% |
| 2024-12-31 | $62.61 Million | $-10.84 Million | -0.173x | -104.90% |
| 2023-12-31 | $-3.88 Million | $-13.70 Million | 3.532x | +451.51% |
| 2022-12-31 | $-23.17 Million | $-14.84 Million | 0.640x | +524.31% |
| 2021-12-31 | $50.76 Million | $-7.66 Million | -0.151x | +89.80% |
| 2020-12-31 | $31.03 Million | $-45.90 Million | -1.479x | -- |
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 cl… Read more